About CH Perpignan
Le centre hospitalier de Perpignan, anciennement hôpital Saint-Jean, est un centre hospitalier situé à Perpignan dans les Pyrénées-Orientales, en région Occitanie.
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Groupe Francophone des Myelodysplasies
13
Federation Francophone de Cancerologie Digestive
11
The Lymphoma Academic Research Organisation
11
Centre Hospitalier Universitaire de Nīmes
9
UNICANCER
6
University Hospital, Toulouse
6
Hoffmann-La Roche
5
Celgene
4
French Innovative Leukemia Organisation
4
Intergroupe Francophone de Cancerologie Thoracique
4
Intergroupe Francophone du Myelome
3
Clinical Trials at CH Perpignan
During the past decade, CH Perpignan conducted 69 clinical trials. In the 10-year time frame, 69 clinical trials started and 11 clinical trials were completed, i.e. on
average, 15.9% percent of trials that started reached the finish line to date. In the past 5 years, 25 clinical trials started and 3 clinical trials were completed. i.e. 12%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer
2004-11-01
2010-06-30
Completed
342
Beluga - Clinical Observations of Automatic Algorithms for Cardiac Pacing
2006-09-01
2010-12-01
Completed
903
Irinotecan With or Without Capecitabine as Second-Line Therapy in Treating Older Patients With Progressive, Metastatic Colorectal Cancer That Cannot Be Removed By Surgery
2006-06-01
Unknown status
78
Combination Chemotherapy as First-Line Therapy in Treating Older Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery
2003-06-01
2011-01-01
Completed
282
Bortezomib and Low Dose Cytarabine in the Treatment of High-Risk Myelodysplastic Syndromes
2006-06-01
2006-06-01
Unknown status
39
Efficacy of an Oral Formula in Prevention of Anti-cancer Therapy Side Effects
2007-10-01
2012-01-01
Completed
Thalidomide at Low Dose for the Treatment of Patient With Myelodysplastic Syndromes - THAL-SMD-200
2003-01-01
2007-03-01
Completed
112
A Study of Bevacizumab (Avastin) in Combination With Rituximab (MabThera) and CHOP (Cyclophosphamide, Hydroxydaunorubicin [Doxorubicin], Oncovin [Vincristine], Prednisone) Chemotherapy in Patients With Diffuse Large B-cell Lymphoma
2007-07-26
2011-11-30
Terminated
787
Clinical Trials Sponsors and Collaborators
Out of the total clinical trials conducted in "CH Perpignan" #1 sponsor was "Groupe Francophone des Myelodysplasies" with 13 trials, followed by "Federation Francophone de Cancerologie Digestive" with 11 trials
sponsored, "The Lymphoma Academic Research Organisation" with 11 trials sponsored, "Centre Hospitalier Universitaire de Nīmes" with 9 trials sponsored and "UNICANCER"
with 9 trials sponsored. Other sponsors include 70 different institutions and
companies that sponsored additional 52 trials in total.
In terms of collaborators to trials, out of the total clinical trials conducted in "CH Perpignan"
#1 collaborator was "Celgene Corporation" with 3 trials as a collaborator, "Janssen-Cilag Ltd." with 3 trials as a collaborator, "Amgen" with 2 trials as a collaborator, "Breast International Group" with 2 trials as a collaborator and "Celgene" with 2 trials as a collaborator. Other collaborators include 114 different institutions and companies that were
collaborators in the rest 114 trials.
Clinical Trials Conditions at CH Perpignan
According to Clinical.Site data, the most researched conditions in "CH Perpignan" are
"Myelodysplastic Syndromes" (7 trials), "Multiple Myeloma" (5 trials), "MDS" (4 trials), "Acute Myeloid Leukemia" (3 trials) and "Breast Cancer" (3 trials). Many other conditions were trialed in "CH Perpignan" in a lesser frequency.
Clinical Trials Intervention Types at CH Perpignan
Most popular intervention types in "CH Perpignan" are "Drug" (80 trials), "Other" (18 trials), "Procedure" (10 trials), "Device" (7 trials) and "Biological" (4 trials). Other intervention types were less common.
The name of intervention was led by "Rituximab" (10 trials), "Cyclophosphamide" (7 trials), "Lenalidomide" (6 trials), "Azacitidine" (4 trials) and "Bendamustine" (4 trials). Other intervention names were less common.
Clinical Trials Genders at CH Perpignan
The vast majority of trials in "CH Perpignan" are
118 trials for "All" genders and 7 trials for "Female" genders.
Clinical Trials Status at CH Perpignan
Currently, there are NaN active trials in "CH Perpignan".
2 are not yet recruiting,
30 are recruiting,
14 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 59 completed trials in CH Perpignan,
undefined suspended trials,
and 10 terminated clinical trials to date.
Out of the total trials that were conducted in CH Perpignan, 5 "Phase 1"
clinical trials were conducted, 41 "Phase 2" clinical
trials and 37 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 2 trials, and there were
also 17 trials that are defined as “Not Applicable".
Departments of CH Perpignan
CH Perpignan has several departments that took part in Clinical trials: "PERPIGNAN - CH St Jean - Hématologie Clinique" - 2 trials, "CH Perpignan, Nephrology department" - 2 trials, "Hopital Saint Jean; Centre Henri Pujol" - 2 trials
Departments List
Name
City
Trials